Gabriella Bond

Gabriella Bond

Auto-generated profile, based on publicly available information

Gabriella Bond

Department of Orthopedic Surgery, Columbia University, New York, NY, USA; Department of Biomedical Engineering, Columbia University, New York, NY, USA

Research Focus & Metrics

Academic Career Length

4Years (2023-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
8 February 2023 in Advanced Healthcare Materials
Verified
Journal Article
Closed access
JLJeremy M. Lowen
Jeremy M. Lowen
GBGabriella C. Bond
Gabriella C. Bond
KGKatherine H. Griffin
Katherine H. Griffin
NSNathan K. Shimamoto
Nathan K. Shimamoto
VTVictoria L. Thai
Victoria L. Thai
JLJ. Kent Leach
J. Kent Leach

7 April 2026 in bioRxiv
Verified
Preprint
Open access
PDF file
GBGabriella Bond
Gabriella Bond
MKMin Kyu M. Kim
Min Kyu M. Kim
LLLauren Lisiewski
Lauren Lisiewski
TJTimothy Jacobsen
Timothy Jacobsen
NCNadeen Chahine
Nadeen Chahine
Intervertebral disc degeneration is associated with loss of nucleus pulposus (NP) cell phenotype and extracellular matrix, both processes linked to changes in cytoskeletal contractility and cell shape. Here, we tested whether microenvironment-specific modulation of RhoA signaling can restore NP-like morphology and gene expression in NP cells cultured in 2D and in 3D alginate. In 2D monolayer culture, where cells are spread and mechanically activated, pharmacologic inhibition of RhoA with CT04 reduced RhoA activity, decreased actomyosin contractility gene expression, and shifted morphology toward a smaller, more circular phenotype. Bulk RNA sequencing showed that CT04 treatment increased expression of NP phenotypic and matrix-related genes including ACAN , GDF5 , CHST3 , and MUSTN1 while decreasing expression of catabolic and fibroblast-associated genes including ADAMTS1/9 and COL1 , consistent with enrichment of extracellular matrix pathways. In contrast, RhoA activation with CN03 in 2D culture increased actin and phosphorylated myosin light chain intensity but produced limited phenotypic improvement. In 3D alginate, which minimizes integrin-mediated adhesion, baseline actomyosin markers were reduced relative to 2D culture. In alginate, RhoA activation with CN03 increased the amount of actin, phosphorylated myosin light chain, and actomyosin gene expression, yet also promoted a more compact, circular morphology and increased NP markers, including ACAN and KRT19 with repeated dosing. Across culture conditions, increased cell roundness was consistently associated with increased ACAN expression, indicating strong coupling between cytoskeletal state, morphology, and NP matrix programs. Together, these findings demonstrate that RhoA pathway perturbation can promote NP phenotypic gene expression in both 2D and 3D culture, but the direction of optimal modulation depends on the microenvironment, supporting RhoA signaling as a context-dependent therapeutic target for disc regeneration.

9 May 2026 in Acta Biomaterialia
Verified
Journal Article
Open access
HBHelna M. Baby
Helna M. Baby
GBGabriella Bond
Gabriella Bond
HCHéctor A.MIllán Cotto
Héctor A.MIllán Cotto
HZHengli Zhang
Hengli Zhang
RNRemya Nair
Remya Nair
ABAmbika G. Bajpayee
Ambika G. Bajpayee
Intervertebral disc degeneration (IVDD) involves dysregulated mechanobiology of nucleus pulposus (NP) cells, marked by disrupted F-actin organization and inflammation-driven extracellular matrix (ECM) catabolism. Restoring actomyosin contractility and cytoskeletal integrity can blunt ECM degradation. Employing a constitutive Rho activator, CN03, reinstates F-actin organization via the RhoA-ROCK pathway and rescues NP cells from cytokine-driven degeneration. However, its constitutive RhoA activity is short-lived, which demands sustained, spatially targeted NP delivery. In this study, an engineered poly-(lactic-co-glycolic) acid microparticle was designed with a viscous inner core (ePLGA-CN03) to encapsulate hydrophilic CN03, minimizing burst and achieving a sustained release profile while preserving bioactivity. In 2D and 3D NP cultures, released CN03 elevated intracellular Ca2+, increased GTP-RhoA, and pMLC to levels comparable to free CN03 and restored F-actin architecture under TNFα stimulation, reducing cell spreading to near control levels. To enhance NP spatial targeting and retention, ePLGA-CN03 was functionalized with cationic avidin (Av-ePLGA-CN03), leveraging electrostatic affinity for the highly anionic, aggrecan-rich NP matrix. Av-ePLGA-CN03 reversed the negative surface charge to cationic, exhibited strong tissue binding, and achieved month-long intra-NP spatial localization in both healthy and degenerated explants, outperforming unmodified particles. Av-ePLGA-CN03 maintained sustained release and remained bioactive. Safety assessments showed no adverse effects on NP swelling properties or cell viability at the effective dose, supporting biocompatibility of avidin functionalization. Collectively, these data demonstrate charge-guided, avidin-modified PLGA depots as a modular approach for sustained, spatially targeted, intra-NP delivery of CN03 and other hydrophilic disease-modifying biologics, supporting future translation evaluation in models of IVD degeneration. STATEMENT OF SIGNIFICANCE: This study engineers a charge-mediated, avidin-anchored, engineered poly-(lactic-co-glycolic) acid microparticle system (Av-ePLGA) designed to selectively bind the aggrecan-rich proteoglycans of the nucleus pulposus (NP), addressing long-standing challenges in tissue-specific drug delivery within the intervertebral disc. This platform achieves spatially confined distribution and month-long retention within the NP while minimizing leakage to adjacent disc regions. The tunable Av-ePLGA carrier accommodates hydrophilic protein biologics, and here we demonstrate efficient encapsulation and sustained release of the Rho-GTP activator CN03 without loss of bioactivity in NP cells. Importantly, surface-anchored cationic charges do not disrupt NP electromechanical integrity. Together, these findings position Av-ePLGA as a promising strategy for spatially targeted, long-acting biologic delivery to the NP.